1. A phase 1 trial of xentuzumab, an IGF‐neutralizing antibody, in Japanese patients with advanced solid tumors. Issue 3 (13th January 2022) Authors: Doi, Toshihiko; Kuboki, Yasutoshi; Naito, Yoichi; Ishida, Masahiro; Tanaka, Tetsuya; Takeuchi, Yoshito Journal: Cancer science Issue: Volume 113:Issue 3(2022) Page Start: 1010 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗